MiNK Therapeutics, Inc. INKT 深 滬
等待開盤 11-04 09:30:00 美东时间
13.45
-0.590
-4.20%
華盛通- 最 高14.25
- 今 開14.25
- 成交量 2.48万股
- 最 低 13.35
- 昨 收 14.04
- 總市值 6083.30万
- 52周最高 76.00
- 市盈率 靜 --
- 換手率 0.55%
- 52周最低 4.632
- 委 比 76.22%
- 總股本 452.29万
- 歷史最高 221.55
- 量 比 1.24
- 振 幅 6.41%
- 歷史最低 4.632
- 每 手 1
- 風險率 5.54%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多MiNK Therapeutics Announces That Late-Breaking Phase 1 Data For Its Allogeneic iNKT Cell Therapy, AgenT-797, Will Be Presented At 40th Annual SITC Meeting Nov 7–9, 2025
MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune disorders, today announced that
10-30 21:03
MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors
MiNK Therapeutics appointed Colonel (Ret.) John B. Holcomb, MD, a global leader in trauma and critical care, to its Board of Directors. Dr. Holcomb brings extensive expertise in immune activation and clinical trial execution, reinforcing MiNK’s commitment to advancing iNKT cell therapies for immune-mediated diseases, pulmonary disorders, and global health security. His leadership will support the company’s mission to address urgent health challen...
09-29 11:30
MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA
MiNK Therapeutics' CEO, Dr. Jennifer Buell, is set to deliver a plenary address at the 10th Annual CAR-TCR Summit in Boston, where she will present groundbreaking data on the company's iNKT cell therapies. Dr. Buell will discuss how these therapies achieve durable disease reversal and steroid-free remission in severe immune collapse, and how MiNK's translational strategy aims to accelerate development in non-oncology indications.
09-25 11:30
MiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal Development
MiNK Therapeutics appoints Terese C. Hammond, MD, as Head of Inflammatory and Pulmonary Diseases, advancing its clinical programs in graft-versus-host disease (GVHD) and severe pulmonary inflammatory disease. Hammond, a leading expert with over 20 years of experience, has contributed to MiNK's iNKT cell therapy research and pivotal studies. Her leadership is expected to accelerate upcoming clinical trials, leveraging her real-world patient insigh...
09-18 11:30
MiNK Therapeutics shares are trading lower after the company reported a Q2 EPS miss.
MiNK Therapeutics shares are trading lower after the company reported a Q2 EPS ...
08-14 20:54
MiNK Therapeutics Q2 EPS $(1.06) Misses $(0.46) Estimate
MiNK Therapeutics (NASDAQ:INKT) reported quarterly losses of $(1.06) per share which missed the analyst consensus estimate of $(0.46) by 132.97 percent. This is a 45.21 percent decrease over losses of $(0.73) per share
08-14 19:33
Earnings Scheduled For August 14, 2025
Companies Reporting Before The Bell • Sunlands Technology (NYSE:STG) is likely ...
08-14 16:32
MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results
MiNK Therapeutics announced Q2 2025 financial results, highlighting a strengthened balance sheet with $1.6 million in cash and $13 million raised post-quarter, extending runway to mid-2026. Key achievements include durable complete remission in metastatic testicular cancer, new grants for GvHD clinical trials, and progress in a Phase 2 gastric cancer study. Net loss was $4.2 million, up from $2.7 million in Q2 2024, reflecting ongoing program act...
08-14 11:30
MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report
<p>MiNK Therapeutics announced it will release its Q2 2025 financial results before the market opens on August 14, 2025. A conference call and webcast will be held at 8:30 a.m. ET that day to discuss the results. The dial-in numbers are 646-307-1963 (New York) and 800-715-9871 (USA & Canada), with conference ID 1149380. A live webcast and replay will be available on the Company’s website.</p>
07-31 12:30
暴涨730%！iNKT疗法用一个临床案例点燃实体瘤革命，中国追赶在即
（来源：求实药社） 2.6亿市值跃升：一个临床案例如何撼动华尔街？ 2025年7月11日，MiNK Therapeutics（NASDAQ: INKT）宣布其异...
07-16 12:01
